Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

vTv Therapeutics to Participate in the 38th Annual ROTH Conference

HIGH POINT, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in a fireside chat and conduct 1x1 investor meetings at the 38th Annual ROTH Conference, which is being held March 22-24, 2026, in Dana Point, CA.

vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement Expect to complete enrollment in the CATT1 Phase 3 trial in the third quarter of 2026  Strengthened balance sheet provides funding runway well past the anticipated CATT1 Phase 3 topline readout HIGH POINT, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes ("T1D"), today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided an update on recent corporate developments.

vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737

Strategic amendment transforms regional partnership into global collaboration; Newsoara gains exclusive worldwide license to develop and commercialize novel PDE4 inhibitor vTv to receive $20 million upfront payment immediately upon execution of the amended license agreement HIGH POINT, N.C., Feb. 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (“T1D”), today announced that it has expanded its license agreement with Newsoara Biopharma Co. Ltd.

vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health

Trial to assess cadisegliatin as potential adjunctive therapy to insulin in patients with T2D Trial to assess cadisegliatin as potential adjunctive therapy to insulin in patients with T2D